-
Breast cancer activism in the United States and the politics of genes
- IJFAB: International Journal of Feminist Approaches to Bioethics
- University of Toronto Press
- Volume 8, Number 1, Spring 2015
- pp. 182-200
- Article
- Additional Information
- Purchase/rental options available:
Perhaps no other medical advocacy movement has been as successful as breast cancer advocacy in increasing awareness and funds. Recent decades have seen a division between a “green” environmental advocacy aimed at prevention and a “pink” advocacy focused on fund-raising for a cure. The movement has largely failed to address the implications of corporate control over genetic testing, as reflected by the involvement of only one breast cancer organization in the lawsuit against Myriad Genetics Laboratory, which held patents on the BRCA 1/2 genes. This article argues that the reason for this failure is an unwillingness to challenge the role that corporations play in advocacy.